Analysts Set Context Therapeutics Inc. (NASDAQ:CNTX) PT at $6.00

Context Therapeutics Inc. (NASDAQ:CNTX) has earned an average rating of “Moderate Buy” from the eight brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $6.00.

A number of brokerages have commented on CNTX. Wall Street Zen raised shares of Context Therapeutics to a “sell” rating in a research note on Saturday, November 22nd. HC Wainwright lifted their price target on Context Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Jones Trading assumed coverage on Context Therapeutics in a research note on Monday, December 22nd. They set a “buy” rating and a $7.00 price objective on the stock. D. Boral Capital restated a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a research report on Thursday, November 6th. Finally, Cantor Fitzgerald initiated coverage on Context Therapeutics in a research note on Thursday, October 2nd. They issued an “overweight” rating for the company.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CNTX. Clear Harbor Asset Management LLC raised its stake in shares of Context Therapeutics by 60.5% in the third quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after acquiring an additional 35,000 shares during the period. Vanguard Group Inc. grew its holdings in Context Therapeutics by 4.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock valued at $3,387,000 after purchasing an additional 134,449 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new stake in Context Therapeutics in the 3rd quarter worth about $100,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Context Therapeutics Price Performance

NASDAQ:CNTX opened at $1.44 on Monday. The company has a market cap of $132.31 million, a price-to-earnings ratio of -6.00 and a beta of 1.91. Context Therapeutics has a 1 year low of $0.49 and a 1 year high of $2.00. The stock’s 50 day simple moving average is $1.24 and its two-hundred day simple moving average is $1.03.

Context Therapeutics (NASDAQ:CNTX) last posted its earnings results on Wednesday, November 5th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). As a group, analysts anticipate that Context Therapeutics will post -0.51 EPS for the current year.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.